Generic Name: Bimatoprost
Class: Prostaglandin Analogs
VA Class: OP109
Chemical Name: (Z)-7-[(1R,2R,3R,5S)-3,5,Dihydroxy-2-[1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-5-N-ethylheptenamide
Molecular Formula: C25H37NO4
Ocular hypotensive agent; a synthetic prostaglandin analog.1
Uses for Lumigan
Ocular Hypertension and Glaucoma
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP-lowering drugs or who have not responded adequately (i.e., failed to achieve target IOP as determined after multiple measurements over time) to another IOP-lowering drug.1
Safety and efficacy not established for the treatment of angle-closure, inflammatory, or neovascular glaucoma.1
At least as effective as latanoprost 0.005% in controlling diurnal IOP;2 7 may be more effective than timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension.2 5
Lumigan Dosage and Administration
Apply topically to the affected eye(s).1
Avoid contamination of the solution container.1
If more than one topical ophthalmic drug is used, administer the drugs at least 5 minutes apart.1
Ocular Hypertension and Glaucoma
One drop of a 0.03% solution in the affected eye(s) once daily in the evening.1 More frequent dosing may paradoxically diminish the IOP-lowering effect of the drug.1
Cautions for Lumigan
Known hypersensitivity to bimatoprost or any ingredient in the formulation.1
Increases in brown pigmentation of the iris and periorbital tissue (eyelid) or increases in length, thickness, number, and pigmentation of eyelashes reported;7 may be permanent.1
Increased pigmentation of iris develops slowly; may not be evident until after several months to years of bimatoprost therapy.1 Long-term effects of these changes are unknown.1 Patients should be examined regularly; therapy may be discontinued if increased pigmentation persists.1
Macular edema, including cystoid macular edema, reported.1 Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.1
Use with caution in patients with active intraocular inflammation (e.g., uveitis).1
Distributed into milk in animals.1 Caution if used in nursing women.1
Safety and efficacy not established in children.1 7
No substantial differences in safety and efficacy relative to younger adults.1
Common Adverse Effects
Conjunctival hyperemia,1 2 growth of eyelashes,1 2 ocular pruritus,1 2 ocular dryness,1 2 visual disturbance,1 ocular burning,1 foreign body sensation,1 ocular pain,1 pigmentation of the periocular skin,1 blepharitis,1 cataract,1 superficial punctate keratitis,1 eyelid erythema,1 ocular irritation,1 eyelash darkening.1
Adverse systemic events include infection (primarily colds and upper respiratory tract infections).1
Interactions for Lumigan
No formal drug interaction studies have been performed.7 The manufacturer states that pharmacokinetic interactions are unlikely.7
Following once-daily topical ocular administration for 2 weeks, peak blood concentrations were attained within 10 minutes and were below the lower limit of detection within 1.5 hours.1 Steady-state blood levels were achieved during the first week of dosing.1
Reduction in IOP generally occurs within 4 hours after topical application and peaks within 8–12 hours.1
Moderately distributed into body tissues with a steady-state volume of distribution of 0.67 L/kg.1 In human blood, bimatoprost resides mainly in the plasma.1
Bimatoprost is distributed into milk in animals; it is not known whether the drug distributes into milk in humans.1
Plasma Protein Binding
Undergoes oxidation, N-deethylation, and glucuronidation to form various metabolites.1
Approximately 67% excreted in urine and 25% excreted in feces after IV administration.1
45 minutes after IV administration.1
15–25°C in the original container.1
Prostamide; a synthetic prostaglandin analog.1 2
Mimics the effects of endogenous prostamides and exhibits little or no pharmacologic activity at prostanoid receptors.1 3 4 7
Appears to reduce intraocular pressure (IOP) by facilitating outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.1 6 7
Advice to Patients
Risk of changes in eyelashes and permanent darkening of iris, eyelashes, or skin around the eyes associated with therapy.1 Potential for disparity between eyes if only one eye is treated.1
Importance of learning and adhering to proper administration techniques to avoid contamination of the solution with common bacteria that can cause ocular infections.1 Serious damage to the eye and subsequent loss of vision may result from using contaminated ophthalmic solutions.1
Importance of informing clinicians if an intercurrent ocular condition (e.g., trauma, infection) develops or ocular surgery is planned.1 Importance of immediately reporting ocular reactions, particularly conjunctivitis and eyelid reactions.1
Importance of delaying insertion of contact lenses for at least 15 minutes after bimatoprost instillation, since benzalkonium chloride preservative may be absorbed by soft lenses.1
Importance of administering different topical ophthalmic preparations at least 5 minutes apart.1
Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.1
Importance of women informing clinicians if they are or intend to become pregnant or plan to breast-feed.1
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Lumigan (with benzalkonium chloride)
AHFS DI Essentials. © Copyright 2018, Selected Revisions July 1, 2007. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
1. Allergan, Inc. Lumigan (bimatoprost) ophthalmic solution 0.03% prescribing information. Irvine, CA; 2001 Mar.
2. Cantor LB. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Expert Opin Investig Drugs. 2001; 10:721-31. [PubMed 11281821]
3. Woodward DF, Krauss AHP, Burk RM et al. Lumigan (AGN 192024): studies on a pharmacologically novel ocular hypotensive agent. Abstract presented at Third International Glaucoma Symposium. Prague, Czech Republic: 2001 Mar 21-5. From .
4. Krauss AHP, Chen J, Woodward DF. The pharmacology of AGN 192024 (Lumigan), a novel ocular hypotensive agent. Abstract presented at Third International Glaucoma Symposium. Prague, Czech Republic: 2001 Mar 21-5. From .
5. Sherwood M, Brandt J for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001; 45(Suppl):S361-8.
6. Brubaker RF, Schoff EO, Nau CB et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Opththalmol. 2001; 131:19-24.
7. Allergan, Irvine, CA: Personal communication.
a. Allergan, Inc. Lumigan (bimatoprost) ophthalmic solution 0.03% prescribing information. Irvine, CA; 2002 May.
More about Lumigan (bimatoprost ophthalmic)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 9 Reviews – Add your own review/rating
- Drug class: ophthalmic glaucoma agents